Seth P. Lerner

35.9k total citations · 7 hit papers
375 papers, 16.4k citations indexed

About

Seth P. Lerner is a scholar working on Surgery, Urology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Seth P. Lerner has authored 375 papers receiving a total of 16.4k indexed citations (citations by other indexed papers that have themselves been cited), including 307 papers in Surgery, 78 papers in Urology and 73 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Seth P. Lerner's work include Bladder and Urothelial Cancer Treatments (294 papers), Urinary and Genital Oncology Studies (189 papers) and Urological Disorders and Treatments (69 papers). Seth P. Lerner is often cited by papers focused on Bladder and Urothelial Cancer Treatments (294 papers), Urinary and Genital Oncology Studies (189 papers) and Urological Disorders and Treatments (69 papers). Seth P. Lerner collaborates with scholars based in United States, Canada and Germany. Seth P. Lerner's co-authors include Shahrokh F. Shariat, Yair Lotan, Arthur I. Sagalowsky, Pierre I. Karakiewicz, Mark Schoenberg, Ashish M. Kamat, Patrick J. Bastian, Amnon Vazina, Ganesh S. Palapattu and Wassim Kassouf and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Seth P. Lerner

359 papers receiving 16.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bladder cancer

2016 1.0k citations Ashish M. Kamat, Noah M. Hahn et al. profile →
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline

2017 613 citations Bernard H. Bochner, Ashish M. Kamat et al. profile →
Outcomes of Radical Cystectomy for Transitional Cell Carcinoma of the Bladder: A Contemporary Series From the Bladder Cancer Research Consortium

2006 509 citations Shahrokh F. Shariat, Pierre I. Karakiewicz et al. profile →
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance

2014 451 citations Seth P. Lerner et al. profile →
Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)

2018 397 citations Bernard H. Bochner, Seth P. Lerner et al. European Urology profile →
Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)

2016 261 citations Francesco Soria, Shahrokh F. Shariat et al. profile →
Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors

2023 222 citations Peter C. Black, Ashish M. Kamat et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Seth P. Lerner United States	66	12.6k	4.0k	3.8k	3.6k	3.0k	375	16.4k
Guido Dalbagni United States	63	12.7k 1.0×	2.8k 0.7×	4.8k 1.3×	3.1k 0.9×	2.6k 0.9×	276	15.3k
Éva Compérat France	59	15.0k 1.2×	4.2k 1.0×	5.0k 1.3×	3.9k 1.1×	6.0k 2.0×	367	20.8k
Ashish M. Kamat United States	69	13.3k 1.1×	4.1k 1.0×	3.8k 1.0×	4.6k 1.3×	3.2k 1.1×	540	18.8k
Maximilian Burger Germany	47	12.4k 1.0×	3.1k 0.8×	3.7k 1.0×	2.8k 0.8×	2.9k 1.0×	258	15.4k
Wassim Kassouf Canada	57	10.2k 0.8×	2.6k 0.6×	3.3k 0.9×	2.7k 0.8×	3.4k 1.1×	380	13.6k
Yves Fradet Canada	65	8.7k 0.7×	3.4k 0.9×	2.1k 0.6×	4.8k 1.3×	5.2k 1.7×	376	16.1k
Richard Zigeuner Austria	54	10.3k 0.8×	3.1k 0.8×	2.9k 0.8×	3.1k 0.9×	5.0k 1.7×	196	14.3k
Colin P. Dinney United States	79	12.9k 1.0×	7.7k 1.9×	3.2k 0.8×	5.8k 1.6×	4.6k 1.5×	492	21.8k
Bas W.G. van Rhijn Netherlands	41	11.0k 0.9×	2.7k 0.7×	3.1k 0.8×	2.3k 0.6×	2.2k 0.7×	141	12.5k
H. Barton Grossman United States	53	7.7k 0.6×	2.8k 0.7×	2.0k 0.5×	2.2k 0.6×	1.8k 0.6×	194	10.6k

Countries citing papers authored by Seth P. Lerner

Since Specialization

Citations

This map shows the geographic impact of Seth P. Lerner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seth P. Lerner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seth P. Lerner more than expected).

Fields of papers citing papers by Seth P. Lerner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seth P. Lerner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seth P. Lerner. The network helps show where Seth P. Lerner may publish in the future.

Co-authorship network of co-authors of Seth P. Lerner

This figure shows the co-authorship network connecting the top 25 collaborators of Seth P. Lerner. A scholar is included among the top collaborators of Seth P. Lerner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seth P. Lerner. Seth P. Lerner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kim, Hyung L., Catherine M. Tangen, Ulka N. Vaishampayan, et al.. (2024). SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]. Urologic Oncology Seminars and Original Investigations. 42. S4–S4. 2 indexed citations

Plimack, Elizabeth R., Catherine M. Tangen, Melissa Plets, et al.. (2024). Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial. European Urology. 86(4). 297–300. 7 indexed citations

Kim, Sung Han, et al.. (2024). Nephron-Sparing Surgery for Upper Urinary Tract Urothelial Carcinoma. SHILAP Revista de lepidopterología. 22(1). 68–77.

Briganti, Alberto, Bradley C. Leibovich, Seth P. Lerner, et al.. (2023). Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023?. European Urology Oncology. 7(3). 412–420. 3 indexed citations

Black, Peter C., Catherine M. Tangen, Parminder Singh, et al.. (2023). Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605. European Urology. 84(6). 536–544. 48 indexed citations

Rose, Kyle, Joshua J. Meeks, Bishoy M. Faltas, et al.. (2023). Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease. Nature Reviews Urology. 20(7). 406–419. 27 indexed citations

Rose, Kyle, Joshua J. Meeks, Bishoy M. Faltas, et al.. (2023). Author Correction: Circulating and urinary tumour DNA in urothelial carcinoma — upper tract, lower tract and metastatic disease. Nature Reviews Urology. 20(7). 452–452. 2 indexed citations

Lerner, Seth P., et al.. (2023). A phase 1, open-label trial to evaluate feasibility and safety of intramural injection of belzupacap sarotalocan (AU-011) in non-muscle–invasive bladder cancer (NMIBC).. Journal of Clinical Oncology. 41(6_suppl). TPS596–TPS596. 1 indexed citations

Lerner, Seth P., et al.. (2022). Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy?. Bladder Cancer. 9(1). 41–48. 1 indexed citations

10.

Flaig, Thomas W., Catherine M. Tangen, Siamak Daneshmand, et al.. (2021). A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695). Clinical Cancer Research. 27(9). 2435–2441. 58 indexed citations

11.

Foerster, Beat, David D‘Andrea, Mohammad Abufaraj, et al.. (2019). Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urologic Oncology Seminars and Original Investigations. 37(7). 430–436. 44 indexed citations

12.

Kates, Max, Andrés Matoso, Woonyoung Choi, et al.. (2019). Adaptive Immune Resistance to Intravesical BCG in Non–Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clinical Cancer Research. 26(4). 882–891. 109 indexed citations

13.

Meeks, Joshua J., Joaquim Bellmunt, Bernard H. Bochner, et al.. (2012). A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. European Urology. 62(3). 523–533. 168 indexed citations

14.

Hoffman, Kristi L., Seth P. Lerner, & C. Smith. (2012). Raloxifene Inhibits Growth of RT4 Urothelial Carcinoma Cells via Estrogen Receptor-Dependent Induction of Apoptosis and Inhibition of Proliferation. Hormones and Cancer. 4(1). 24–35. 42 indexed citations

15.

Stadler, Walter M., Seth P. Lerner, Susan Groshen, et al.. (2011). Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status. Journal of Clinical Oncology. 29(25). 3443–3449. 165 indexed citations

16.

Sabichi, Anita L., J. Jack Lee, H. Barton Grossman, et al.. (2011). A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer. Cancer Prevention Research. 4(10). 1580–1589. 42 indexed citations

17.

Jian, Weiguo, et al.. (2008). Comparison of the 5637 human urothelial cancer cell line with a second-generation 5637 cell line for cancer therapy. Cancer Research. 68. 2711–2711. 1 indexed citations

18.

Sabichi, Anita L., Seth P. Lerner, E. Neely Atkinson, et al.. (2006). Phase III bladder cancer chemoprevention trial with fenretinide.. Cancer Epidemiology and Prevention Biomarkers. 15. 1 indexed citations

19.

Shariat, Shahrokh F., et al.. (2003). Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 61(6). 1140–1145. 99 indexed citations

20.

Link, Richard E. & Seth P. Lerner. (2001). Rebuilding the lower urinary tract after cystectomy: a roadmap for patient selection and counseling.. PubMed. 19(1). 24–36. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact